PURPOSE: For classical Hodgkin lymphoma (HL), migrant studies could elucidate contributions of environmental factors (including Epstein-Barr virus (EBV)) to the lower rates in non-whites. Given the well-described etiologic complexity of HL, this research requires a large, immigrant population, such as California Hispanics. METHODS: With 1988-2004 California Cancer Registry data (2,595 Hispanic, 8,637 white HL cases) and tumor cell EBV status on a subset (218 Hispanics, 656 whites), we calculated ethnicity- and nativity-specific HL incidence rates simultaneously by age, sex, and histologic subtype, and tumor cell EBV prevalence. RESULTS: Compared with white rates, Hispanic HL rates were lower overall (70 %) and for nodular sclerosis HL, particularly among young adults (60-65 % for females). However, they were higher among children (200 %) and older adults, and for mixed cellularity HL. Compared with rates in foreign-born Hispanics, rates in US-born Hispanics were higher among young adults (>threefold in females), lower for children and adults over age 70, and consistently intermediate compared with rates in whites. EBV tumor prevalence was 67, 32, and 23 % among foreign-born Hispanics, US-born Hispanics, and whites, respectively, although with variation by age, sex, and histology. CONCLUSIONS: Findings strongly implicate environmental influences, such as nativity-related sociodemographic differences, on HL occurrence. In addition, lower young adult rates and higher EBV prevalence in US-born Hispanics than in whites raise questions about the duration/extent of environmental change for affecting HL rates and also point to ethnic differences in genetic susceptibility. Lesser variation in mixed cellularity HL rates and greater variation in rates for females across groups suggest less modifiable factors interacting with environmental influences.
PURPOSE: For classical Hodgkin lymphoma (HL), migrant studies could elucidate contributions of environmental factors (including Epstein-Barr virus (EBV)) to the lower rates in non-whites. Given the well-described etiologic complexity of HL, this research requires a large, immigrant population, such as California Hispanics. METHODS: With 1988-2004 California Cancer Registry data (2,595 Hispanic, 8,637 white HL cases) and tumor cell EBV status on a subset (218 Hispanics, 656 whites), we calculated ethnicity- and nativity-specific HL incidence rates simultaneously by age, sex, and histologic subtype, and tumor cell EBV prevalence. RESULTS: Compared with white rates, Hispanic HL rates were lower overall (70 %) and for nodular sclerosis HL, particularly among young adults (60-65 % for females). However, they were higher among children (200 %) and older adults, and for mixed cellularity HL. Compared with rates in foreign-born Hispanics, rates in US-born Hispanics were higher among young adults (>threefold in females), lower for children and adults over age 70, and consistently intermediate compared with rates in whites. EBV tumor prevalence was 67, 32, and 23 % among foreign-born Hispanics, US-born Hispanics, and whites, respectively, although with variation by age, sex, and histology. CONCLUSIONS: Findings strongly implicate environmental influences, such as nativity-related sociodemographic differences, on HL occurrence. In addition, lower young adult rates and higher EBV prevalence in US-born Hispanics than in whites raise questions about the duration/extent of environmental change for affecting HL rates and also point to ethnic differences in genetic susceptibility. Lesser variation in mixed cellularity HL rates and greater variation in rates for females across groups suggest less modifiable factors interacting with environmental influences.
Authors: Scarlett Lin Gomez; Sally L Glaser; Laura A McClure; Sarah J Shema; Melissa Kealey; Theresa H M Keegan; William A Satariano Journal: Cancer Causes Control Date: 2011-02-12 Impact factor: 2.506
Authors: Christina A Clarke; Sally L Glaser; Theresa H M Keegan; Antoinette Stroup Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-06 Impact factor: 4.254
Authors: Rohina Rubicz; Robert Yolken; Eugene Drigalenko; Melanie A Carless; Thomas D Dyer; Lara Bauman; Phillip E Melton; Jack W Kent; John B Harley; Joanne E Curran; Matthew P Johnson; Shelley A Cole; Laura Almasy; Eric K Moses; Nikhil V Dhurandhar; Ellen Kraig; John Blangero; Charles T Leach; Harald H H Göring Journal: PLoS Genet Date: 2013-01-10 Impact factor: 5.917
Authors: Connor Graham; Catherine Metayer; Libby M Morimoto; Joseph L Wiemels; Arfan Siddique; Mengyang Di; Rozalyn L Rodwin; Nina S Kadan-Lottick; Xiaomei Ma; Rong Wang Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-09-02 Impact factor: 4.090
Authors: A A Gru; B H Haverkos; A G Freud; J Hastings; N B Nowacki; C Barrionuevo; C E Vigil; R Rochford; Y Natkunam; R A Baiocchi; P Porcu Journal: Curr Hematol Malig Rep Date: 2015-12 Impact factor: 3.952
Authors: Mahdi Nohtani; Katerina Vrzalikova; Maha Ibrahim; Judith E Powell; Éanna Fennell; Susan Morgan; Richard Grundy; Keith McCarthy; Sarah Dewberry; Jan Bouchal; Katerina Bouchalova; Pamela Kearns; Paul G Murray Journal: Cancers (Basel) Date: 2022-09-01 Impact factor: 6.575
Authors: Humberto Parada; Andrew H Vu; Paulo S Pinheiro; Caroline A Thompson Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-07-28 Impact factor: 4.254
Authors: Sally L Glaser; Christina A Clarke; Theresa H M Keegan; Ellen T Chang; Dennis D Weisenburger Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-07-27 Impact factor: 4.090
Authors: Renata Abrahão; Ruth H Keogh; Daphne Y Lichtensztajn; Rafael Marcos-Gragera; Bruno C Medeiros; Michel P Coleman; Raul C Ribeiro; Theresa H M Keegan Journal: Br J Haematol Date: 2016-02-05 Impact factor: 8.615